These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19196394)

  • 1. Molecular basis of therapeutic approaches to gastric cancer.
    Wu K; Nie Y; Guo C; Chen Y; Ding J; Fan D
    J Gastroenterol Hepatol; 2009 Jan; 24(1):37-41. PubMed ID: 19196394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer.
    Peng Z; Wei D; Wang L; Tang H; Zhang J; Le X; Jia Z; Li Q; Xie K
    Clin Cancer Res; 2006 Nov; 12(21):6386-94. PubMed ID: 17085650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
    Chan MW; Wong CY; Cheng AS; Chan VY; Chan KK; To KF; Chan FK; Sung JJ; Leung WK
    Oncol Rep; 2007 Dec; 18(6):1557-62. PubMed ID: 17982644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reappraisal of the impacts of human Runt-related transcription factor gene 3 expression on differentiation and prognosis of gastric cancer].
    Wu BW; Zhang J; Fei XF; Zhu ZG; Cao WX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Mar; 10(2):165-8. PubMed ID: 17380460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer.
    Hsu PI; Hsieh HL; Lee J; Lin LF; Chen HC; Lu PJ; Hsiao M
    Ann Surg Oncol; 2009 Jun; 16(6):1686-94. PubMed ID: 19290488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
    Gong M; Lu Z; Fang G; Bi J; Xue X
    Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression status of RUNX1/AML1 in normal gastric epithelium and its mutational analysis in microdissected gastric cancer cells.
    Usui T; Aoyagi K; Saeki N; Nakanishi Y; Kanai Y; Ohki M; Ogawa K; Yoshida T; Sasaki H
    Int J Oncol; 2006 Oct; 29(4):779-84. PubMed ID: 16964375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization.
    Ito K; Liu Q; Salto-Tellez M; Yano T; Tada K; Ida H; Huang C; Shah N; Inoue M; Rajnakova A; Hiong KC; Peh BK; Han HC; Ito T; Teh M; Yeoh KG; Ito Y
    Cancer Res; 2005 Sep; 65(17):7743-50. PubMed ID: 16140942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Runx3 controls growth and differentiation of gastric epithelial cells in mammals.
    Fukamachi H
    Dev Growth Differ; 2006 Jan; 48(1):1-13. PubMed ID: 16466388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 and gastric cancer.
    Thiel A; Mrena J; Ristimäki A
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):387-95. PubMed ID: 22002749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies in gastric cancer.
    Wong JE; Ito Y; Correa P; Peeters KC; van de Velde CJ; Sasako M; Macdonald J
    J Clin Oncol; 2003 Dec; 21(23 Suppl):267s-269s. PubMed ID: 14645406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D; Farrow B; Berger DH
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis.
    Wei D; Gong W; Oh SC; Li Q; Kim WD; Wang L; Le X; Yao J; Wu TT; Huang S; Xie K
    Cancer Res; 2005 Jun; 65(11):4809-16. PubMed ID: 15930301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Runx3 is a key event in inducing precancerous state of the stomach.
    Ito K; Chuang LS; Ito T; Chang TL; Fukamachi H; Salto-Tellez M; Ito Y
    Gastroenterology; 2011 May; 140(5):1536-46.e8. PubMed ID: 21277301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth regulation of gastric epithelial cells by Runx3.
    Fukamachi H; Ito K
    Oncogene; 2004 May; 23(24):4330-5. PubMed ID: 15156189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription-based COX-2 inhibition: a therapeutic strategy.
    Wu KK
    Thromb Haemost; 2006 Oct; 96(4):417-22. PubMed ID: 17003917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1A physically interacts with RUNX3 and inhibits its transactivation activity.
    Cha EJ; Oh BC; Wee HJ; Chi XZ; Goh YM; Lee KS; Ito Y; Bae SC
    J Cell Biochem; 2008 Sep; 105(1):236-44. PubMed ID: 18570183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.